GB2414668B - Tetracycline modified release delivery system - Google Patents

Tetracycline modified release delivery system

Info

Publication number
GB2414668B
GB2414668B GB0419500A GB0419500A GB2414668B GB 2414668 B GB2414668 B GB 2414668B GB 0419500 A GB0419500 A GB 0419500A GB 0419500 A GB0419500 A GB 0419500A GB 2414668 B GB2414668 B GB 2414668B
Authority
GB
United Kingdom
Prior art keywords
tetracycline
delivery system
modified release
release delivery
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB0419500A
Other versions
GB0419500D0 (en
GB2414668A (en
Inventor
Victor Pevzner
Marina Ruderman
Avi Avramoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcel Ltd
Original Assignee
Dexcel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57630604P priority Critical
Application filed by Dexcel Ltd filed Critical Dexcel Ltd
Publication of GB0419500D0 publication Critical patent/GB0419500D0/en
Publication of GB2414668A publication Critical patent/GB2414668A/en
Application granted granted Critical
Publication of GB2414668B publication Critical patent/GB2414668B/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/471The waterborne disease being caused by a bacteria the bacteria being Vibrio cholerae, i.e. Cholera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/473The waterborne disease being caused by a bacteria the bacteria being Escherichia coli, i.e. E. coli Infection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/475The waterborne disease being caused by a bacteria of the genus Shigella, i.e. Dysentery
GB0419500A 2004-06-03 2004-09-02 Tetracycline modified release delivery system Active GB2414668B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US57630604P true 2004-06-03 2004-06-03

Publications (3)

Publication Number Publication Date
GB0419500D0 GB0419500D0 (en) 2004-10-06
GB2414668A GB2414668A (en) 2005-12-07
GB2414668B true GB2414668B (en) 2009-07-29

Family

ID=33159923

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0419500A Active GB2414668B (en) 2004-06-03 2004-09-02 Tetracycline modified release delivery system

Country Status (1)

Country Link
GB (1) GB2414668B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8268804B2 (en) 2005-06-24 2012-09-18 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP2017517592A (en) * 2014-04-08 2017-06-29 ダウ グローバル テクノロジーズ エルエルシー Dispersion containing esterified cellulose ether

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1858488E (en) 2005-03-14 2013-11-18 Wyeth Llc Tigecycline compositions and methods of preparation
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
EP1965770A2 (en) * 2005-12-22 2008-09-10 Wyeth a Corporation of the State of Delaware Oral formulations comprising tigecycline
AU2007208214B2 (en) * 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
WO2008121107A1 (en) * 2007-04-02 2008-10-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20120027855A1 (en) * 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
PT2271348T (en) * 2008-03-28 2018-04-16 Paratek Pharm Innc Oral tablet formulation of tetracycline compound
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
DE102011075354A1 (en) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Dosage form comprises at least one first active substance-containing unit, and at least one second active substance-containing unit, and both units comprise a first active substance
EA025128B1 (en) 2011-05-05 2016-11-30 Хенниг Арцнаймиттель Гмбх Унд Ко. Кг Dosage form for the controlled release of active ingredients
CN105534941A (en) * 2016-01-04 2016-05-04 浙江美华鼎昌医药科技有限公司 Minocycline hydrochloride sustained release tablets and preparation method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0310814A2 (en) * 1987-10-06 1989-04-12 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
EP0418565A2 (en) * 1989-09-21 1991-03-27 American Cyanamid Company Pulsatile once-a-day delivery system for minocycline
EP0558913A1 (en) * 1992-03-02 1993-09-08 American Cyanamid Company Improved pulsatile once-a-day delivery systems for minocycline
US20020136766A1 (en) * 2000-02-24 2002-09-26 Rudnic Edward M. Tetracycline antibiotic product, use and formulation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0310814A2 (en) * 1987-10-06 1989-04-12 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
EP0418565A2 (en) * 1989-09-21 1991-03-27 American Cyanamid Company Pulsatile once-a-day delivery system for minocycline
EP0558913A1 (en) * 1992-03-02 1993-09-08 American Cyanamid Company Improved pulsatile once-a-day delivery systems for minocycline
US20020136766A1 (en) * 2000-02-24 2002-09-26 Rudnic Edward M. Tetracycline antibiotic product, use and formulation thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268804B2 (en) 2005-06-24 2012-09-18 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP2017517592A (en) * 2014-04-08 2017-06-29 ダウ グローバル テクノロジーズ エルエルシー Dispersion containing esterified cellulose ether

Also Published As

Publication number Publication date
GB0419500D0 (en) 2004-10-06
GB2414668A (en) 2005-12-07

Similar Documents

Publication Publication Date Title
GB2416049B (en) Document delivery
TWI363845B (en) Illumination system
TWI356888B (en) Illumination system
GB2453455B (en) Controllable release nasal system
EG24185A (en) System for releasing complex assemblies
IL197360A (en) Securing distributed application information delivery
EP1784302A4 (en) Encapsulated cure systems
EP1701669A4 (en) Stent delivery device
EP1817655A4 (en) Visual system
HK1117014A1 (en) Targeted biopsy delivery system
EP1942831A4 (en) Twist-down implant delivery technologies
EP1890755A4 (en) Mask system
EP1851653A4 (en) Fuel dispensing system
EP1889198A4 (en) Pharma-informatics system
EP2061261A4 (en) Stereoprojection system
EP1763697A4 (en) Illumination systems
EP1837792A4 (en) Management system
EP1895992A4 (en) Compressible gum based delivery systems for the release of ingredients
EP1960618A4 (en) Anchoring system for posts
EP1809362A4 (en) Filter delivery system
EP1807018A4 (en) In situ controlled release drug delivery system
EP1800959A4 (en) Display system
TWI301180B (en) Delivery device
GB2420044B (en) Viewing system
GB0523814D0 (en) Checklist system